August 2012
-
Pharmaxis will collaborate with the Woolcock Institute of Medical Research to develop a tobramycin dry powder inhaler for the treatment of cystic fibrosis, the company has announced. A A$421,545 grant from the Australian National Health… Read more . . .
-
According to MannKind Corporation, it has reached an agreement with Sanofi regarding the return of rights to Afrezza inhaled insulin, in which “All issues arising out of the license and collaboration agreement, the supply agreement,… Read more . . .
-
Irish science center AMBER (Advanced Materials and BioEngineering Research), located at Trinity College Dublin, has announced that investigator Anne Marie Healy has received a €600,000 grant from the US National Institutes of Health (NIH) for… Read more . . .
-
Mucosis has initiated a Phase 1 study of its SynGEM intranasal respiratory syncytial virus (RSV) vaccine, the company said. In January 2016, Mucosis announced that it had received a €3.7 million grant from the Wellcome… Read more . . .
-
Submit 500 word abstracts by February 11, 2017. See http://www.inhalationasia.org/conference/inhalation-asia-2017-from-13-to-15-september-2017-in-Hong-Kong/present for a list of topics and submission form. Read more . . .
-
According to numerous sources, Teleflex Medical has voluntarily recalled multiple lots of its LMA MAD intranasal delivery device because the devices are failing to aerosolize the drug. The recall notification says, “Teleflex Medical is recalling… Read more . . .
-
Propeller Health has announced that its inhaler monitoring platform has received 510(k) clearance from the FDA for use with the Ellipta dry powder inhaler. The company had announced a deal with GSK to develop a… Read more . . .
-
Inhaler testing automation company Astech Projects has announced the delivery of a fully automated robotic workstation for shot weight testing of DPIs based on its Xelair 1 Series automation platform. The system rotates each device… Read more . . .
-
Spyryx Biosciences has presented data from preclinical studies of its SPX-101 inhaled SPLUNC1-derived peptide showing that SPX-101 improves mucus clearance and survival in animal models of cystic fibrosis and demonstrated no toxicity. The data were… Read more . . .
-
Connected device company Cohero Health has closed a $9M Series A financing round to fund development of its BreatheSmart platform, business development, and clinical trials, the company said. One of the company’s new investors is… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland